Abstract
Many patients with coronary heart disease undergo percutaneous transluminal coronary angioplasty (PTCA) to improve myocardial tissue perfusion. However, a major complication after revascularisation procedures is restenosis of the injured artery. The molecular mechanism involved is not fully elucidated and no successful treatment is currently available. Animal models are preliminary tools that can help improve our understanding of the pathogenesis and treatment of restenosis in humans. Attracted by well-defined genetic systems, a number of investigators began to use the mouse as an experimental system for restenosis research. They demonstrated that several stages involved in this process include thrombus formation, inflammatory cell infiltration and smooth muscle cell (SMC) accumulation to form neointimal lesions. By using transgenic and knockout mice a number of genes related to these processes have been found to play a major role in mediating lesion formation, e.g. the plasminogen system, matrix metalloproteinases (MMP), adhesion molecules, cytokines and signal transducers. This review will not attempt to cover all aspects of related genes or molecules, but will rather focus on several groups of genes, by which the major progress in understanding the mechanisms of the disease has been made. The information obtained by using animal models could be essential for a better understanding of the pathogenesis of restenosis in humans and to provide a basis for therapeutic intervention.
Keywords: PCTA, restenosis, animal models, genetic manipulation
Current Vascular Pharmacology
Title: The Molecular Mechanisms of Vascular Restenosis: Which Genes are Crucial?
Volume: 4 Issue: 3
Author(s): Jemma Bhoday, Sampath de Silva and Qingbo Xu
Affiliation:
Keywords: PCTA, restenosis, animal models, genetic manipulation
Abstract: Many patients with coronary heart disease undergo percutaneous transluminal coronary angioplasty (PTCA) to improve myocardial tissue perfusion. However, a major complication after revascularisation procedures is restenosis of the injured artery. The molecular mechanism involved is not fully elucidated and no successful treatment is currently available. Animal models are preliminary tools that can help improve our understanding of the pathogenesis and treatment of restenosis in humans. Attracted by well-defined genetic systems, a number of investigators began to use the mouse as an experimental system for restenosis research. They demonstrated that several stages involved in this process include thrombus formation, inflammatory cell infiltration and smooth muscle cell (SMC) accumulation to form neointimal lesions. By using transgenic and knockout mice a number of genes related to these processes have been found to play a major role in mediating lesion formation, e.g. the plasminogen system, matrix metalloproteinases (MMP), adhesion molecules, cytokines and signal transducers. This review will not attempt to cover all aspects of related genes or molecules, but will rather focus on several groups of genes, by which the major progress in understanding the mechanisms of the disease has been made. The information obtained by using animal models could be essential for a better understanding of the pathogenesis of restenosis in humans and to provide a basis for therapeutic intervention.
Export Options
About this article
Cite this article as:
Bhoday Jemma, de Silva Sampath and Xu Qingbo, The Molecular Mechanisms of Vascular Restenosis: Which Genes are Crucial?, Current Vascular Pharmacology 2006; 4 (3) . https://dx.doi.org/10.2174/157016106777698397
DOI https://dx.doi.org/10.2174/157016106777698397 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Proteomic Analysis of Endothelin-1 Targets in the Regulation of Cardiomyocyte Proliferation
Current Topics in Medicinal Chemistry The Role of Dairy Products in Healthy Weight and Body Composition in Children and Adolescents
Current Nutrition & Food Science Interleukin-6 In Rheumatoid Arthritis - From The Laboratory To The Bedside
Current Pharmaceutical Design Vitamin D in Atherosclerosis, Vascular Disease, and Endothelial Function
Current Drug Targets The Role of T-Helper Cells in Atherosclerosis
Cardiovascular & Hematological Agents in Medicinal Chemistry A Review on Natural Sources Derived Protein Nanoparticles as Anticancer Agents
Current Topics in Medicinal Chemistry Pleiotropic Effects of Cytokines on Acute Myocardial Infarction: G-CSF as A Novel Therapy for Acute Myocardial Infarction
Current Pharmaceutical Design Mediterranean Diet and Dementia of the Alzheimer Type
Current Aging Science Physiological Significance and Therapeutic Potential of Adrenomedullin in Pulmonary Hypertension
Cardiovascular & Hematological Disorders-Drug Targets Potential Therapeutic Effects of Na+/Ca2+ Exchanger Inhibition in Cardiac Diseases
Current Medicinal Chemistry Prognostic Relevance of Metabolic Approach in Patients with Heart Failure
Current Pharmaceutical Design Myocardial Contrast Echocardiography: Role in Clinical Cardiology
Current Vascular Pharmacology Anthracycline-Induced Cardiotoxicity
Cardiovascular & Hematological Agents in Medicinal Chemistry The Role of Inflammation and Allergy in Acute Coronary Syndromes
Inflammation & Allergy - Drug Targets (Discontinued) Cardiovascular Morbidity and Mortality in Obstructive Sleep Apnea
Current Pharmaceutical Design Mesenchymal Stem Cells: A New Generation of Therapeutic Agents as Vehicles in Gene Therapy
Current Gene Therapy COVID-19: Our Current Knowledge of Epidemiology, Pathology, Therapeutic Approaches, and Diagnostic Methods
Anti-Cancer Agents in Medicinal Chemistry Effects of Ox Bile Extract on the Phospholipids and Fatty Acids Membrane Composition of Salmonella enterica Serovar Typhimurium seqA Mutant Strain
Current Chemical Biology Editorial [ Cardiovascular Risk Factor Modification: A sine qua non in the Management of Vascular Surgery Patients ]
Current Vascular Pharmacology Cardiac Involvement in ANCA (+) and ANCA (-) Churg-Strauss Syndrome Evaluated by Cardiovascular Magnetic Resonance
Inflammation & Allergy - Drug Targets (Discontinued)